NEW YORK – Spatial genomics startup Vizgen said on Thursday that it has raised $37 million in an oversubscribed Series B financing.
Novalis LifeSciences and Northpond Ventures led the round, joined by new investors Tao Capital Partners, Pura Vida Investments, and an unspecified US endowment fund as well as existing investors Arch Venture Partners and David Walt. Walt, a professor at Harvard Medical School, is a Vizgen cofounder and board member.